214 related articles for article (PubMed ID: 30082069)
1. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
2. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
3. ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
Gao H; Marhefka C; Jacobs MD; Cao J; Bandarage UK; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2616-2621. PubMed ID: 29945794
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
[TBL] [Abstract][Full Text] [Related]
8. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).
Sessions EH; Chowdhury S; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7113-8. PubMed ID: 22018789
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological characterization of selective LIMK inhibitors.
Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Vanormelingen J; Fransen S; Van de Velde S; Defert O
Bioorg Med Chem Lett; 2015 Sep; 25(18):4005-10. PubMed ID: 26233434
[TBL] [Abstract][Full Text] [Related]
12. Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.
Judge RA; Vasudevan A; Scott VE; Simler GH; Pratt SD; Namovic MT; Putman CB; Aguirre A; Stoll VS; Mamo M; Swann SI; Cassar SC; Faltynek CR; Kage KL; Boyce-Rustay JM; Hobson AD
Chembiochem; 2018 Mar; 19(6):613-621. PubMed ID: 29314498
[TBL] [Abstract][Full Text] [Related]
13. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
Kast R; Schirok H; Figueroa-Pérez S; Mittendorf J; Gnoth MJ; Apeler H; Lenz J; Franz JK; Knorr A; Hütter J; Lobell M; Zimmermann K; Münter K; Augstein KH; Ehmke H; Stasch JP
Br J Pharmacol; 2007 Dec; 152(7):1070-80. PubMed ID: 17934515
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents.
Yao Y; Li R; Liu X; Yang F; Yang Y; Li X; Shi X; Yuan T; Fang L; Du G; Jiao X; Xie P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29048389
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.
Abbhi V; Saini L; Mishra S; Sethi G; Kumar AP; Piplani P
Bioorg Med Chem; 2017 Nov; 25(21):6071-6085. PubMed ID: 29033348
[TBL] [Abstract][Full Text] [Related]
17. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
[TBL] [Abstract][Full Text] [Related]
18. The development of benzimidazoles as selective rho kinase inhibitors.
Sessions EH; Smolinski M; Wang B; Frackowiak B; Chowdhury S; Yin Y; Chen YT; Ruiz C; Lin L; Pocas J; Schröter T; Cameron MD; LoGrasso P; Feng Y; Bannister TD
Bioorg Med Chem Lett; 2010 Mar; 20(6):1939-43. PubMed ID: 20167489
[TBL] [Abstract][Full Text] [Related]
19. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
Feng Y; LoGrasso PV; Defert O; Li R
J Med Chem; 2016 Mar; 59(6):2269-300. PubMed ID: 26486225
[TBL] [Abstract][Full Text] [Related]
20. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
